Arrowhead Pharmaceuticals Inc
Veridion Score
Composite trend over time
Why is ARWR moving today?
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
Real vendor fields plus Veridion-computed history. Missing fields stay blank.
Warehouse intelligence for ARWR.
ARWR insider activity
Arrowhead Pharmaceuticals Inc
No multi-insider buying cluster in the last 90 days
Net selling: -$37.6M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-14 | 2026-05-12 | Lu Hongbo | Insider | sell | $76.88 | 2,970 | 52,012 | $228K | SEC Form 4 |
| 2026-04-24 | 2026-04-23 | Hamilton James C | Insider | sell | $75.00 | 10,000 | 226,958 | $750K | SEC Form 4 |
| 2026-04-24 | 2026-04-22 | Apel Daniel Joseph | Insider | sell | $71.92 | 8,730 | 162,905 | $628K | SEC Form 4 |
| 2026-04-24 | 2026-04-22 | Apel Daniel Joseph | Insider | sell | $70.45 | 1,157 | 171,635 | $82K | SEC Form 4 |
| 2026-04-24 | 2026-04-22 | Apel Daniel Joseph | Insider | sell | $70.11 | 3,208 | 172,792 | $225K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 64 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moARWR contract awards, year to date.
Public federal awards linked to this ticker.
ARWR lobbying filings, year to date.
Registered lobbying filings matched to Arrowhead Pharmaceuticals Inc.